1型格子状角膜营养不良患者使用环孢素滴眼液：病例报告
Cyclosporine eye drops in lattice corneal dystrophy type 1: case report.
作者信息
Al-Hawasli Hasan, Tarbouche Raghid
机构信息
Scientific Affairs Deputy Manager, Oubari Habboush Pharma, Damascus, Syria.
Eye and Ear Hospital, Damascus, Syria.
出版信息
Ann Med Surg (Lond). 2025 Jul 22;87(9):6127-6130. doi: 10.1097/MS9.0000000000003625. eCollection 2025 Sep.
INTRODUCTION AND IMPORTANCE
To report a successful treatment of lattice corneal dystrophy type 1 (LCD1) using topical cyclosporine (CsA) eye drop emulsion 0.05%.
CASE PRESENTATION
A 48-year-old female patient presented with bilateral LCD1characterized by corneal stromal lattice lines and visual symptoms. The patient was treated with topical CsA 0.05% twice daily for 3 months, followed by once daily for another 3 months.
CLINICAL DISCUSSION
Following treatment, the patient experienced a significant improvement in symptoms and resolution of corneal opacities in the treated eye.
CONCLUSION
This case report demonstrates the potential efficacy of topical CsA as a novel treatment option for LCD1, offering a noninvasive approach to manage symptoms and improve visual function. Further studies are needed to confirm these findings.
引言与重要性
报告使用0.05%环孢素（CsA）滴眼液乳剂成功治疗1型格子状角膜营养不良（LCD1）的病例。
病例介绍
一名48岁女性患者，双侧患有以角膜基质格子状线条和视觉症状为特征的LCD1。患者接受0.05% CsA滴眼液每日两次治疗3个月，随后每日一次再治疗3个月。
临床讨论
治疗后，患者症状显著改善，患眼角膜混浊消退。
结论
本病例报告证明局部使用CsA作为LCD1的一种新型治疗选择具有潜在疗效，为管理症状和改善视觉功能提供了一种非侵入性方法。需要进一步研究以证实这些发现。
Zotero 插件